Healthcare / Medical DevicesTaiwan
$72.00
-0.60 (-0.83%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-124.2M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-43.9%
↓Gross Margin
24.9%
↓Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+149.2%
FCF CAGR
—
FCF margin
-123.9%
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $100.2M · net income $-126.1M · FCF $-124.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $100.2M | $100.2M | $141.6M | $9.2M | $6.5M |
| Net Income | $-126.1M | $-126.1M | $-78.2M | $-165.9M | $-143.8M |
| EBITDA | $-104.0M | $-104.0M | $-26.6M | $-142.9M | $-129.9M |
| EPS | — | — | -2.60 | -6.21 | -6.62 |
| Gross Margin | 24.9% | 24.9% | 70.4% | -283.1% | -475.0% |
| Operating Margin | -119.4% | -119.4% | -26.6% | -1556.6% | -2253.8% |
| Net Margin | -125.8% | -125.8% | -55.2% | -1796.7% | -2219.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.39 | 0.39 | 0.04 | 0.06 | 0.02 |
| Current Ratio | 4.81 | 4.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-124.2M | $-124.2M | $-43.9M | $-128.0M | $-88.4M |
| Returns | |||||
| ROE | -43.9% | -43.9% | -37.4% | -59.9% | -79.5% |
| Valuation | |||||
| P/B | 8.20 | 8.20 | 11.91 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -29.2% | -29.2% | 1433.4% | 42.6% | — |
| EPS Growth | — | — | 58.2% | 6.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+20.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.60 → n/d
Residual
+20.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.